Aldesleukin Withdrawn Phase 1 Trials for Metastatic Melanoma Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02489266In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma